Skip to main content

Table 1 Changes of the main clinical outcomes before and after treatment (mean ± sd)

From: Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients

 TimeCombinedp*ZOLp*MTXp*
Morning stiffness (min)0 M92.21 ± 47.6981.29 ± 35.5689.97 ± 36.42
6 M21.34 ± 16.10< 0.00171.27 ± 14.890.37144.15 ± 13.990.021
12 M13.09 ± 14.43< 0.00142.69 ± 13.560.01925.19 ± 14.21< 0.001
A.1.1.1.1.1.1. VAS (mm)0 M64.36 ± 18.2963.94 ± 17.8365.28 ± 17.27
6 M37.90 ± 14.04< 0.00143.02 ± 16.200.04040.08 ± 15.880.048
12 M29.23 ± 16.13< 0.00137.02 ± 17.89< 0.00138.72 ± 17.25< 0.001
A.1.1.1.1.1.2. ESR(mm/h)0 M49.87 ± 27.6850.43 ± 34.7852.25 ± 37.96
 6 M30.61 ± 21.560.02240.25 ± 28.750.46737.21 ± 25.470.038
 12 M23.58 ± 17.870.00838.67 ± 22.870.36336.24 ± 21.460.023
A.1.1.1.1.1.3. CRP(mg/L)0 M25.14 ± 22.2323.67 ± 27.3526.21 ± 28.38
 6 M13.57 ± 15.890.03118.52 ± 29.510.07715.39 ± 26.290.035
 12 M8.60 ± 12.270.02918.78 ± 23.380.07911.02 ± 20.120.019
A.1.1.1.1.1.4. DAS280 M7.21 ± 1.277.17 ± 1.216.36 ± 1.45
 6 M4.89 ± 1.26**< 0.0015.11 ± 1.330.0364.27 ± 1.310.032
 12 M4.17 ± 1.21**< 0.0014.67 ± 1.280.0194.12 ± 1.270.021
  1. Note: VAS visual analog scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS 28 disease activity scores-28; *p values indicate the comparison with that before treatment within the same group; indicates p < 0.05 for the comparison between two groups at the same time point on their difference over the treatment